BioPortfolio Provides:

  • comprehensive market data
  • up to date reports
  • personal "find a report" service
  • reliable and quick

Contact us with your report needs NOW!

+44 843 557 6440
priority@bioportfolio.com

BioPortfolio Specialist Market Reports:
Biotechnology, Life Science
Healthcare and Pharmaceutical
Market Research and Corporate Data

Search our store now...

Life Science market research and business reports

Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?Lingering concerns have been hanging over AstraZeneca’s Onglyza and Takeda’s Nesina since 2013 when detailed analyses from respective cardiovascular (CV) outcomes studies suggested the DPP-IV inhibitors may be associated with an increased risk of heart failure.On April 14, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee finally provided some semblance…...read more

Trends & Innovations Sales Force EffectivenessWhat makes an ideal modern pharma sales representative and what skills, knowledge, tools, training and incentives will make them really effective?Trends and Innovations in Sales Force Effectiveness is an important report for anyone looking to optimise their field sales force performance. This reports offers critical insights for sales and training…...read more

Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectivesIt all started years ago, with a few patients asking questions on the internet. These days, patient self-education and engagement in treatment and disease management has become a powerful behaviour not just for themselves, but for physicians, pharma and payers alike.FirstWord explores how pharma is meeting the challenge of patient-centricity…...read more

Physician Views: What commercial impact for Eylea from the Protocol T study in diabetic macular oedema?It seems that controversy over the use of off-label Avastin as a much cheaper alternative to Lucentis for the treatment of various ophthalmic indications is never far from the surface.A recent article published by the British Medical Journal claims that Novartis (which markets Lucentis in Europe) sought to block studies…...read more

Biosimilars: US Payer Perspectives…pulls back the curtain on the US biologics market and provides detailed and actionable insights from 12 expert US payers from a range of different organisations, including Pharmacy Benefit Managers, Managed Care Organisations and Integrated Delivery Networks. In addition, receive an Advisory Highlights management summary which covers key findings from…...read more

Physician Views: CMS guidance on biosimilar reimbursement – what do oncologists and rheumatologists think?Recent FDA approval of the first US biosimilar product has spurred the Centers for Medicare and Medicaid Services (CMS) to publish new guidance relating to biosimilar reimbursement and usage (ViewPoints: New CMS documents should grease the wheels of adoption for biosimilars).Under Medicare Part B, where products are administered by physicians…...read more

Physician Views: What scope for the next oral RA therapy?…rheumatoid arthritis (RA) market is one of the largest in the pharmaceutical sector and is dominated by biologic therapies, primarily the TNF inhibitors. The three largest products in this category – AbbVie's Humira, Johnson & Johnson and Merck & Co.'s Remicade, and Amgen and Pfizer's Enbrel – were positioned among…...read more

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US)FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5) provides cutting edge, advanced and proprietary analytics that companies operating in the MS space need to develop, shape and refine brand strategy. Critically, the report quantifies the impact and influence of specific environmental barriers – such as price…...read more

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5)FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US) provides cutting edge, advanced and proprietary analytics that companies operating in the MS space need to develop, shape and refine brand strategy.Critically, the report quantifies the impact and influence of specific environmental barriers – such as price, availability…...read more

Rheumatoid Arthritis: KOL Insight…RA landscape will experience significant change over the next five years as biosimilar versions of the blockbuster anti-TNFs and new products all vie for market share with current treatment options. Biomarkers are also likely to emerge as a critical influence in treatment decision making, allowing physicians to stratify patients and…...read more

Trends and Innovations in Patient AdherenceTaking the right dose of the right medicine at the right time is key to improving health outcomes, so why do so many patients fail to adhere to their treatment programme?Trends and Innovations in Patient Adherenceis a thought-provoking and comprehensive report for everyone involved in ensuring patients comply with taking…...read more

Nonalcoholic Steatohepatitis: KOL InsightWhy This Report is Essential Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs…...read more

Physician Views: Is Esperion's ETC-1002 a viable threat to the PCSK9 inhibitors if mid-stage data are replicated in Phase III studies?Last week saw Esperion Therapeutics release promising Phase IIb data for its oral hypercholesterolaemia treatment ETC-1002. When added to stable statin therapy, a 180mg dose of ETC-1002 demonstrated a 24 percent incremental reduction in LDL-cholesterol versus those patients treated only with a statin, while a lower 120mg dose demonstrated a…...read more

Physician Views: How comfortable are doctors with the commercial use of gene therapy?Gene therapy has been around for decades, yet in a sense the concept has recently been made to feel new again thanks to some notable breakthroughs and milestones, not least of which was the European marketing approval for uniQure and Chiesi’s Glybera (alipogene tiparvovec) issued in late 2012 – the…...read more

Physician Views: Will PEGASUS data make AstraZeneca's Brilinta fly?Despite the publication of full data from AstraZeneca's PEGASUS-TIMI 54 study this weekend, their remains mixed views as to whether trial results will drive a significant increase in the use of the platelet aggregation inhibitor Brilinta.The PEGASUS study has been designed to evaluate whether the continued treatment of acute coronary…...read more

Payer Perspectives on Risk Sharing DealsRisk sharing agreements have been a strategic tool employed for more than a decade. Yet, they’re still widely misunderstood — and underutilized, especially as they may help provide access to a frugal, risk-averse marketplace. Are you up to speed on all that a risk sharing agreement might do for your…...read more

Physician Views: Oncologists react to approval of Zarxio – the first US biosimilarFollowing unanimous recommendation from the FDA's Oncologic Drugs Advisory Committee (ODAC) in mid-January, FDA approval for Novartis' Zarxio – announced on Friday – came as little surprise (ViewPoints: Approval of the first US biosimilar – the key questions).Approval does highlight, however, a number of regulatory factors that are likely to…...read more

Physician Views: What impact will new Kyprolis data have on MM treatment paradigm?Amgen has been under fire ever since announcing plans to acquire Onyx for $10.4 billion as the Street has consistently questioned whether the US drugmaker will be able to achieve the type of growth with multiple myeloma (MM) drug Kyprolis (carfilzomib) – the crown jewel of the acquisition – necessary…...read more

Physician Views – Defining a suitable NASH therapyExcitement around the opportunity for therapies that are designed to treat nonalcoholic steatohepatitis (NASH) continues to grow and with little surprise.Due to the lack of approved or satisfactory treatments, as well as the increasing prevalence of this disease, there remains high unmet in the treatment of NASH and therefore, high…...read more

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory DisordersBased on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various…...read more

The Rise of Wearable Healthcare Technology: Opportunities and Challenges for PharmaIn The Rise of Wearable Healthcare Technology: Opportunities and Challenges for Pharma, FirstWord examines an emerging industry that is predicted to generate $53.2 billion in global sales by 2019.Considered a perfect convergence of mobile tech trends and real-time data, wearables are already shaping the future of healthcare. Based on in-depth…...read more

Trends and Innovations in Lifecycle Management…(LCM) presents business-critical insights for strategic planners and marketers based on the opinions of eight leading pharma industry, legal and consulting experts. Gain insights on current LCM practice and learn from their practical experience to understand key considerations for developing, establishing and managing an effective lifecycle management (LCM) strategy.With the…...read more

Physician Views – Sanofi secures US Toujeo approval, but are endocrinologists convinced?As expected, Sanofi's incoming CEO will have a shiny new product franchise to launch when he takes the helm in April. The French company confirmed on Wednesday that Toujeo – a more potent version of its $7 billion-a-year Lantus franchise – has been approved by the FDA and will reach…...read more

Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight the potential cost of treatment to the US healthcare system associated with a new class of dyslipidaemia therapies called PCSK9 inhibitors. The two most advanced drugs in this class – Sanofi and Regeneron Pharmaceuticals' alirocumab and…...read more

Renal Cell Carcinoma: KOL InsightWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights on what leading clinicians think about current treatment options, new therapies, the critical role of…...read more

Easy Payment Options

We accept the following credit cards...
Visa Credit payments supported by WorldPayVisa Debit payments supported by WorldPayMastercard payments supported by WorldPayAmerican Express payments supported by WorldPayWorldPay Payments Processing

Or we can raise a pro forma invoice if you prefer.

Buy With Confidence

BioPortfolio has been selling market reports for over 16 years from the world's leading market research companies.

Personal Service

Our team will work with you to source the best report for your needs. We can liaise with publishers to obtain sample pages and negotiate discounts where available.

Market Leader

With over 15,000 visitors to our websites every day, BioPortfolio is the world's leading biotech, healthcare and medical resource online.